Peak Bio Inc. is a clinical-stage biopharmaceutical company, which engages in the commercialization of therapeutics that aim to address the medical need of patients with inflammatory, rare and specialty diseases, and cancer. It focuses on the development of treatment of alpha-1 antitrypsin (AAT) deficiency (AATD), a genetic disorder that may result in lung disease or liver disease. The company is headquartered in Pleasanton, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company